Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4260574 | 0.97 | DNM1 (0.50) | DNM1MEN1KMT2ATHRBTHRA | |
| SCHEMBL627232 | 0.97 | DNM1 (0.50) | DNM1MEN1KMT2ATHRBTHRA | |
| SCHEMBL12791104 | 0.97 | DNM1 (0.50) | DNM1MEN1KMT2ATHRBTHRA | |
| SCHEMBL12791152 | 0.97 | DNM1 (0.50) | DNM1MEN1KMT2ATHRBTHRA | |
| SCHEMBL2322366 | 0.97 | DNM1 (0.50) | DNM1MEN1KMT2ATHRBTHRA | |
| SCHEMBL12791220 | 0.97 | DNM1 (0.50) | DNM1MEN1KMT2ATHRBTHRA | |
| SCHEMBL9398013 | 0.97 | DNM1 (0.50) | DNM1MEN1KMT2ATHRBTHRA | |
| SCHEMBL21126455 | 0.97 | DNM1 (0.50) | DNM1MEN1KMT2ATHRBTHRA | |
| SCHEMBL20746956 | 0.97 | DNM1 (0.50) | DNM1MEN1KMT2ATHRBTHRA | |
| SCHEMBL20142522 | 0.97 | DNM1 (0.50) | DNM1MEN1KMT2ATHRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3071575-B1 | PREPARATION OF NORMORPHINANS | SpecGx LLC (US) | 2019-11-13 | — | — | EP | claimed |
| US-12115161-B2 | Prophylactic and/or therapeutic agent for inflammatory diseases which contains pyrrolopyrimidine compound as active ingredient | KEIO UNIVERSITY (JP) | 2024-10-15 | — | — | US | disclosed |
| US-12077631-B2 | Bulk polymerisation of polyoxazolidone | BASF SE (DE) | 2024-09-03 | — | — | US | disclosed |
| CN-112424253-B | Bulk polymerization of polyoxazolidinones | 巴斯夫欧洲公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-112119063-B | Method for producing 3-difluoromethylpyrazole compound, method for producing 3-difluoromethylpyrazole-4-carboxylic acid compound, and pyrazolidine compound | 富士胶片株式会社 | 2023-10-17 | — | — | CN | disclosed |
| US-20230304002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | BANK OF AMERICA, N.A. | 2023-09-28 | — | — | US | disclosed |
| US-11696953-B2 | Poly(beta-amino esters) and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-07-11 | — | — | US | disclosed |
| WO-2023101722-A1 | NOVEL AZA-SUBSTITUTED PSILOCIN ANALOGS AND METHODS OF SYNTHESIZING THE SAME | MEDECINE INNOVATIONS GROUP INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023063175-A1 | HYDROGENATION FLAVOR-IMPARTING AGENT AND METHOD FOR PRODUCING SAME, METHOD FOR IMPARTING HYDROGENATION FLAVOR TO FOOD, USE OF OXIDIZED PRODUCT FOR IMPARTING HYDROGENATION FLAVOR TO FOOD, AND FOOD CONTAINING HYDROGENATION FLAVOR-IMPARTING AGENT | 株式会社Ｊ－オイルミルズ | 2023-04-20 | — | — | WO | disclosed |
| EP-3824012-B1 | BULK POLYMERISATION OF POLYOXAZOLIDONE | BASF SE (DE) | 2022-09-07 | — | — | EP | disclosed |
| EP-1470136-B1 | METHOD FOR THE SEPARATION OF ACIDS FROM CHEMICAL REACTION MIXTURES BY MEANS OF IONIC FLUIDS | BASF AG (DE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006108861-A2 | SOLUBILITY OF CELLULOSE IN IONIC LIQUIDS WITH ADDITION OF AMINO BASES | BASF AKTIENGESELLSCHAFT (DE) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006061188-A1 | PURIFICATION OF IONIC LIQUIDS | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006029884-A1 | METHOD FOR OPERATING A LIQUID RING COMPRESSOR | BASF AKTIENGESELLSCHAFT (DE) | 2006-03-23 | — | — | WO | disclosed |
| US-20050020857-A1 | Removal by salt formation | BASF AKTIENGESELLSCHAFT (DE) | 2005-01-27 | — | — | US | disclosed |
| EP-1472201-A2 | METHOD FOR THE SEPARATION OF ACIDS FROM CHEMICAL REACTION MIXTURES BY MEANS OF IONIC FLUIDS | BASF AKTIENGESELLSCHAFT (DE) | 2004-11-03 | — | — | EP | disclosed |
| EP-1470136-A1 | METHOD FOR THE SEPARATION OF ACIDS FROM CHEMICAL REACTION MIXTURES BY MEANS OF IONIC FLUIDS | BASF AKTIENGESELLSCHAFT (DE) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003062171-A2 | METHOD FOR THE SEPARATION OF ACIDS FROM CHEMICAL REACTION MIXTURES BY MEANS OF IONIC FLUIDS | BASF AKTIENGESELLSCHAFT (DE) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003062251-A1 | METHOD FOR THE SEPARATION OF ACIDS FROM CHEMICAL REACTION MIXTURES BY MEANS OF IONIC FLUIDS | BASF AKTIENGESELLSCHAFT (DE) | 2003-07-31 | — | — | WO | disclosed |
| US-5472880-A | Adding a sterically hindered base to the solvent inducing the ionization of free amino acid, quantitatively measuring the conductivity | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 1995-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12115161-B2 | Prophylactic and/or therapeutic agent for inflammatory diseases which contains pyrrolopyrimidine compound as active ingredient | TPMT, IL1B, TSLP | DNM1 2701/4885MEN1 2642/4885KMT2A 3934/4885 |
| US-20050020857-A1 | Removal by salt formation | PHOSPHO1, AASDHPPT, INPP5B | DNM1 2824/4885MEN1 1135/4885KMT2A 1005/4885 |
| US-20230304002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | TTR, MTPN, CRYAA | DNM1 3780/4885MEN1 3220/4885KMT2A 4228/4885 |
| US-11696953-B2 | Poly(beta-amino esters) and uses thereof | BCAT1, BCAT2, SNRPE | DNM1 2479/4885MEN1 4493/4885KMT2A 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.